The efficacy of postoperative bio-chemoradiotherapy using cetuximab and docetaxel for cis-platinum intolerant high-risk head and neck cancer patients.
Not Applicable
Recruiting
- Conditions
- The efficacy of postoperative bio-chemoradiotherapy using cetuximab and docetaxel for cis-platinum intolerant high-risk head and neck cancer patients.
- Registration Number
- JPRN-UMIN000031835
- Lead Sponsor
- Yokohama City University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
Prior to enrollment in this trial, the patients must not meet any of the following criteria: uncurable synchronous malignancies, priority systemic diseases, and refusal to undergo the definitive surgery and/or postoperative radiotherapy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 2-year disease free survival
- Secondary Outcome Measures
Name Time Method 2-year overall survival, 2-year recurrence free survival, and 2-year locoregional control survival